PRKAA1 and metabolic dysfunction-associated steatotic liver disease: As shown in Fig. 6A-B, the body weight gain in the NAFLD + AMPK-IN-3 group was higher than that in the NAFLD + DMSO group (P < 0.001), suggesting that suppression of AMPK activity aggravated NAFLD-related metabolic disturbances.